These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15818507)

  • 1. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
    Kirstein MN; Panetta JC; Gajjar A; Nair G; Iacono LC; Freeman BB; Stewart CF
    Cancer Chemother Pharmacol; 2005 May; 55(5):433-8. PubMed ID: 15818507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
    Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
    Beale P; Judson I; Moore S; Statkevich P; Marco A; Cutler DL; Reidenberg P; Brada M
    Cancer Chemother Pharmacol; 1999; 44(5):389-94. PubMed ID: 10501912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
    Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
    J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
    Reid JM; Stevens DC; Rubin J; Ames MM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children.
    Turner PK; Iacono LC; Panetta JC; Santana VM; Daw NC; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):475-82. PubMed ID: 16047146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
    Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
    Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
    Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
    Ma J; Pulfer S; Li S; Chu J; Reed K; Gallo JM
    Cancer Res; 2001 Jul; 61(14):5491-8. PubMed ID: 11454697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
    Tsang LL; Quarterman CP; Gescher A; Slack JA
    Cancer Chemother Pharmacol; 1991; 27(5):342-6. PubMed ID: 1998993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and pharmacokinetics of temozolomide in rat.
    Reyderman L; Statkevich P; Thonoor CM; Patrick J; Batra VK; Wirth M
    Xenobiotica; 2004 May; 34(5):487-500. PubMed ID: 15370964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
    Diez BD; Statkevich P; Zhu Y; Abutarif MA; Xuan F; Kantesaria B; Cutler D; Cantillon M; Schwarz M; Pallotta MG; Ottaviano FH
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):727-34. PubMed ID: 19641919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
    Rudek MA; Donehower RC; Statkevich P; Batra VK; Cutler DL; Baker SD
    Pharmacotherapy; 2004 Jan; 24(1):16-25. PubMed ID: 14740784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
    Broniscer A; Iacono L; Chintagumpala M; Fouladi M; Wallace D; Bowers DC; Stewart C; Krasin MJ; Gajjar A
    Cancer; 2005 Jan; 103(1):133-9. PubMed ID: 15565574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
    Zhou Q; Guo P; Kruh GD; Vicini P; Wang X; Gallo JM
    Clin Cancer Res; 2007 Jul; 13(14):4271-9. PubMed ID: 17634557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
    Chowdhury SK; Laudicina D; Blumenkrantz N; Wirth M; Alton KB
    J Pharm Biomed Anal; 1999 Apr; 19(5):659-68. PubMed ID: 10698531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic activation of temozolomide measured in vivo using positron emission tomography.
    Saleem A; Brown GD; Brady F; Aboagye EO; Osman S; Luthra SK; Ranicar AS; Brock CS; Stevens MF; Newlands E; Jones T; Price P
    Cancer Res; 2003 May; 63(10):2409-15. PubMed ID: 12750260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
    Broniscer A; Gururangan S; MacDonald TJ; Goldman S; Packer RJ; Stewart CF; Wallace D; Danks MK; Friedman HS; Poussaint TY; Kun LE; Boyett JM; Gajjar A
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6712-8. PubMed ID: 18006772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.